Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Snyder

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Journal for Immunotherapy of Cancer|July 20, 2024
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers CommitteeAnne Monette, Sarah Warren, J Carl Barrett, et al.
Cancer Cell|September 12, 2023
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progressionBrian G Topp, Madhav Channavazzala, Kapil Mayawala, et al.
Gynecologic Oncology Reports|February 11, 2022
Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancerRami Vanguri, Jamal Benhamida, Jonathan H Young, et al.
Journal of the American Society of Nephrology : JASN|December 5, 2009
The ubiquitin-like protein FAT10 mediates NF-kappaB activationPengfei Gong, Allon Canaan, Bin Wang, et al.
Journal for Immunotherapy of Cancer|February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumorsRazvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Cell Reports|April 12, 2018
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive ClassesAlexander Solovyov, Nicolas Vabret, Kshitij S Arora, et al.
Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.
JCO Precision Oncology|September 11, 2020
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian CancerYuki Himoto, Harini Veeraraghavan, Junting Zheng, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|July 20, 2024
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers CommitteeAnne Monette, Sarah Warren, J Carl Barrett, et al.
Cancer Cell|September 12, 2023
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progressionBrian G Topp, Madhav Channavazzala, Kapil Mayawala, et al.
Gynecologic Oncology Reports|February 11, 2022
Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancerRami Vanguri, Jamal Benhamida, Jonathan H Young, et al.
Journal of the American Society of Nephrology : JASN|December 5, 2009
The ubiquitin-like protein FAT10 mediates NF-kappaB activationPengfei Gong, Allon Canaan, Bin Wang, et al.
Journal for Immunotherapy of Cancer|February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumorsRazvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.
Cell Reports|April 12, 2018
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive ClassesAlexander Solovyov, Nicolas Vabret, Kshitij S Arora, et al.
Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.
JCO Precision Oncology|September 11, 2020
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian CancerYuki Himoto, Harini Veeraraghavan, Junting Zheng, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Pageof 8